Practical Review of Biologics in Chronic Rhinosinusitis With Nasal Polyps

Abstract

Well-characterized in chronic rhinosinusitis, type 2 inflammation is frequently associated with nasal polyps, comorbid asthma, and nonsteroidal anti-inflammatory drug hypersensitivity. Despite medical and surgical treatment, it recurs in a significant proportion of patients. Thus, severe uncontrolled type 2 chronic rhinosinusitis with nasal polyps is the most difficult-to-treat phenotype of chronic rhinosinusitis. Recently, dupilumab, a monoclonal antibody against IL-4 receptor α, and omalizumab, a monoclonal antibody against immunoglobulin E, were approved for patients with chronic rhinosinusitis with nasal polyps in the United States, Europe, and Korea. Therefore, rhinologists should understand novel biologics and their use. Here, we provide a literature review of several biologics with their indications, effectiveness, and safety.

Formulation and Characterization of Intranasal Drug Delivery of Frovatriptan-Loaded Binary Ethosomes Gel for Brain Targeting

“…The chosen dispersion exhibited physicochemical properties well-suited to lipid BE used in the preparations. 69,70 The reported pH value of the investigated formula was (5.3 ± 0.03) within the acceptable range of the successful nasal formulation (between 5.3 and 7.0 71 ). All the prepared BE dispersion formulas (G1 -G7) appeared as a homogenous creamy suspension without precipitation or aggregation with a characteristic ethanol odor, as illustrated by Table 4.…”